Reported 8 months ago
Fady Boctor, President and Chief Commercial Officer of Petros Pharmaceuticals, anticipates a potential threefold increase in the prescription erectile dysfunction market if an erectile dysfunction therapy is made available over-the-counter (OTC). Boctor revealed that nearly 75% of men in the U.S. avoid seeking prescription ED treatment due to stigma, creating an opportunity to address the needs of the 30 million men in the U.S. with ED. Petros aims to transition their ED therapy to OTC status and tap into the growing Rx-to-OTC switch market, envisioned by FMI to reach $66.5 billion by 2033. Petros Pharmaceuticals is also exploring future OTC opportunities in women's health and facing challenges in differentiating themselves from non-FDA-approved products in the men's health market.
Source: YAHOO